---
title: "Kymera Therapeutics to Participate in Guggenheim Biotech Summit and Oppenheimer Healthcare Conference"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274807457.md"
datetime: "2026-02-04T12:01:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274807457.md)
  - [en](https://longbridge.com/en/news/274807457.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274807457.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274807457.md) | [English](https://longbridge.com/en/news/274807457.md)


# Kymera Therapeutics to Participate in Guggenheim Biotech Summit and Oppenheimer Healthcare Conference

Kymera Therapeutics Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY on February 11 at 9:00 a.m. ET and the Oppenheimer Virtual 36th Annual Healthcare Life Sciences Conference on February 26 at 2:00 p.m. ET. Live webcasts of these presentations will be available on the company’s website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648466-en) on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Kymera Therapeutics (KYMR.US)](https://longbridge.com/zh-HK/quote/KYMR.US.md)

## 相關資訊與研究

- [Capricor Theraputics Q4 revenue falls to zero, net loss widens](https://longbridge.com/zh-HK/news/278939139.md)
- [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/zh-HK/news/278565253.md)
- [Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs](https://longbridge.com/zh-HK/news/278102320.md)
- [UCB reports superiority of bimekizumab in psoriatic arthritis study](https://longbridge.com/zh-HK/news/278691960.md)
- [Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference](https://longbridge.com/zh-HK/news/278285380.md)